Study to evaluate if eculizumab is efficient and safe enough to be used for treatment of adults with atypical hemolytic-uremic syndrome

Phase 2

• Conditions: Atypical Hemolytic-Uremic Syndrome; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12611000498998
• Lead Sponsor: Alexion Pharmaceuticals Australasia Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-05-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients must be willing to give written informed consent.
Patients must be over 18 years of age with a diagnosis of atyipcal hemolytic-uremic syndrome.
Patients exhibit thrombocytopenia, hemolysis and elevated serum creatinine.

Exclusion Criteria

Chronic dialysis.
Prior eculizumab use or hypersensitivity to eculizumab, to murine proteins or to one of the excipients.

Study & Design

• Study Type: Interventional
• Study Design: Not specified